Pfizer (PFE) Stock Price
Pfizer Price
Over the last 19 years Pfizer grew revenue by 1.4% annually, reaching 62.58 B USD. Earnings per share have declined at 0.6% per year over the last 19 years. For Pfizer, the net margin of 12.4% is down versus 27.2% a few years ago. At today's price the dividend yield works out to roughly 6.19%. The payout ratio is around 126% of earnings. The dividend has grown at 3.1% per year over the past 19 years. The consensus 12-month price target for Pfizer is 27.00 USD, about 2.9% below where the stock trades today. Of 36 analysts, 14 rate the stock a buy — an overall Hold consensus.
Pfizer stock price
Pfizer business model & stock analysis
Frequently asked questions about Pfizer
Pfizer Inc's business model is focused on pharmaceutical research, development, manufacturing, and sales. The company operates in various therapeutic areas, including but not limited to oncology, cardiovascular, immunology, and neurology. Pfizer's mission is to discover and develop innovative medicines that enhance the health and well-being of people worldwide. With a diverse portfolio of prescription medicines, vaccines, and consumer healthcare products, Pfizer strives to improve patient outcomes and provide effective healthcare solutions. Through strategic partnerships and collaborations, Pfizer continues to invest in research and development to address unmet medical needs and drive sustainable growth in the pharmaceutical industry.
Pfizer Inc is primarily active in the pharmaceutical industry.
The main competitors of Pfizer Inc in the market include pharmaceutical companies such as Johnson & Johnson, Novartis AG, Merck & Co., Inc., and GlaxoSmithKline plc.
Pfizer Inc. is a renowned pharmaceutical giant with a rich history and influential background. Established in 1849, Pfizer has evolved into one of the largest global pharmaceutical companies. Headquartered in New York City, Pfizer has played a pivotal role in the healthcare industry's advancement. The company is committed to developing innovative medicines and vaccines that improve and save lives worldwide. With its vast expertise, extensive research and development efforts, and strategic collaborations, Pfizer has introduced groundbreaking treatments for various diseases. As a leader in the pharmaceutical sector, Pfizer continues to prioritize delivering transformative healthcare solutions to address the evolving needs of patients and healthcare professionals.
Pfizer Inc has achieved significant milestones throughout its history. Founded in 1849, the company has become one of the world's leading pharmaceutical corporations. Notably, Pfizer developed and marketed groundbreaking drugs that have revolutionized medical treatments. In 1998, the company gained immense recognition with the introduction of Viagra, a medication for erectile dysfunction. Pfizer's research and innovation also led to the development of Lipitor, a cholesterol-lowering drug that became the best-selling prescription medicine worldwide. Furthermore, Pfizer remains dedicated to advancing healthcare by continuously expanding its product portfolio and pursuing collaborations to address unmet medical needs. With its rich history and commitment to innovation, Pfizer Inc continues to make significant contributions to the healthcare industry.
Pfizer Inc is primarily present in various countries and regions across the globe. The company has a widespread presence with operations in multiple key markets. Pfizer's global presence includes major countries such as the United States, United Kingdom, Germany, Japan, China, India, Brazil, and many more. With a diverse international footprint, Pfizer Inc continues to serve patients and healthcare professionals worldwide by delivering innovative healthcare solutions and medications.
Pfizer Inc, a renowned pharmaceutical company, represents values of integrity, excellence, and patient-centricity. With a strong corporate philosophy, Pfizer aims to improve the health and well-being of individuals worldwide through innovative medicines and therapies. Committed to scientific advancement, Pfizer provides quality healthcare solutions while upholding ethical practices. Through extensive research and development, they strive to discover and deliver life-saving and life-enhancing treatments. As a global leader in the healthcare industry, Pfizer's dedication to patient care, scientific ingenuity, and ethical principles are fundamental to their corporate philosophy and drive their mission to revolutionize healthcare for a better tomorrow.
Analysts currently set an average price target of 27.38 USD for the Pfizer stock (median: 27.00 USD), implying -1.5 % versus the latest price. The consensus is based on 36 analyst ratings.
36 analysts currently rate the Pfizer stock: 14 recommend buying, 20 holding and 2 selling. For 2026, analysts expect Pfizer to generate revenue of 62.25 B USD and earnings per share of 2.99 USD.
Converted at the current exchange rate, the Pfizer share trades at 24.71 EUR (27.80 USD).
The Pfizer share (PFE) is listed on 13 stock exchanges, including: NYSE (PFE), London (0Q1N.L), SIX (Zürich) (PFE.SW), XETRA (PFE.DE), Frankfurt (PFE.F), München (PFE.MU), Stuttgart (PFE.SG), Düsseldorf (PFE.DU).
Pfizer Inc is a multinational pharmaceutical company headquartered in New York City. The company operates in the research, development, production, and distribution of drugs. Pfizer is one of the largest pharmaceutical companies in the world. In this article, we will describe the business model of Pfizer Inc. Divisions Pfizer has divided its business operations into three main divisions: Biopharmaceuticals, Beyond the Baby Cure, and Contract Manufacturing. Biopharmaceuticals The Biopharmaceuticals division focuses on the research and development of drugs. The goal is to develop new drugs and therapies that meet the needs of patients. Research and development are focused on various areas such as oncology, cardiovascular, immunological, and neuroscience disorders. Pfizer has a strong pipeline with numerous drugs in late-stage clinical development. An example is the drug Tofacitinib, which is used to treat rheumatoid arthritis. In 2020, Pfizer generated revenue of $51.8 billion in this division. Beyond the Baby Cure The Beyond the Baby Cure division refers to products that are not drug-based. This includes products like vitamin-rich dietary supplements, pain relievers, condoms, and personal care products. Pfizer acquired Wyeth in 2006, a company active in this segment. This allowed Pfizer to expand its product portfolio. In 2020, Pfizer generated revenue of $2.5 billion in this segment. Contract Manufacturing Pfizer's Contract Manufacturing division refers to the production of drugs for other companies. The company offers services for the entire value chain, from drug manufacturing to logistics. In 2020, Pfizer generated revenue of $2.2 billion in this division. Products Pfizer offers a wide range of products covering various areas. Here are some of Pfizer's key products: - Viagra, a medication for the treatment of erectile dysfunction - Lyrica, a medication for the treatment of neuropathic pain - Prevnar, a vaccine for the prevention of pneumococcal infections - Xeljanz, a medication for the treatment of rheumatoid arthritis - Lipitor, a medication for lowering cholesterol levels Conclusion Pfizer is a leading pharmaceutical company with a broad portfolio of products and services. The company specializes in three main divisions: Biopharmaceuticals, Beyond the Baby Cure, and Contract Manufacturing. With a strong commitment to research and development and an impressive pipeline, Pfizer has a strong position in the industry.
The expected revenue of Pfizer is 62.25 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Pfizer is 17.00 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Pfizer is currently 9.30. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pfizer stock.
The price-to-sales ratio (P/S) of Pfizer is currently 2.54. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pfizer stock.
The Eulerpool Quality Score for Pfizer is 1/10.
The ISIN of Pfizer is US7170811035. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Pfizer is 852009. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Pfizer is PFE. The ticker symbol is used to trade Pfizer shares on the stock exchange.
Pfizer stock
Pfizer Peer Group
Pfizer Ticker
Pfizer FIGI
All fundamentals and in-depth analysis of Pfizer
Our stock analysis for Pfizer stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pfizer. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.